Welcome to the SWYAPC website

The information on these pages is intended as a guide only. Whilst we endeavour to keep such information as up to date as possible, we make no claim as to its total accuracy or completeness. Information is liable to change, and such changes may not be mirrored in this site. We do not accept liability for any loss or damage resulting from use of this site or reliance on its content. External links lead to sites and pages over which we have no control, and which we cannot verify for accuracy or content. The inclusion of a link on this website should not be taken as an endorsement of the linked website, nor of the accuracy or quality of the information on such sites.

Updates following the November 2018 Area Prescribing Committee Meeting

Red, Amber, Green Classifications:



Flash glucose monitoring system – now been approved for patients with Type 1 diabetes who fulfil the criteria. Now Red.

Anakinra – New indication. Red for patients with gout who have contra-indications to standard treatment.

Midostaurin – Red for accute FLT 3-mutation-positive myeloid leukaemia.

Alectinib – Red for untreated anaplastic ALK-positive, advanced non-small-cell lung cancer in adults.

Inotuzumab – Red for relapsed or refractory CD22-positive, B cell precursor acute lymphoblastic leukaemia.

Pembrolizumab – New indication. Red for adults with relapsed or refractory classical Hodgkin lymphoma who are stem cell transplant ineligible and have failed on brentuximab vedotin.

Baricitinib – New indication. Red for moderate to severe active rheumatoid arthritis in adults who have responded inadequately to or are intolerant to one or more DMARDs.


Azathioprine – changed from Red to Amber for use post-transplant.

Green Specialist Initiation

Eslicarbazepine – GSI for epilepsy.

Oxcarbazepine – GSI for epilepsy.

Refinimide – GSI for epilepsy.

Perampanel – GSI for epilepsy.


Nefopam – Black for pain.

ActiPatch® – Black for pain.

Cannabis based products (not sativex®) – New guidance from NHS England.

Xonvea® – Black for nausea and vomiting in pregnancy.

VSL#3 – now Black for management of GI symptoms in adults.


The ratified minutes from the August meeting have been added to the business section of the website for information.

Commissioning Position – Flash Glucose Monitoring Systems – November 2018

The expected cost of the Flash Glucose Monitoring Systems to the NHS is over £900 per patient per year of continuous use compared with £360 – £650 per patient per year for finger pricking (based on testing 4-8 times per day). Therefore, it is currently unaffordable and unsustainable to make it available for all people with diabetes.

Bradford City and Districts CCGs, Calderdale CCG, Greater Huddersfield CCG, North Kirklees CCG and Wakefield CCG and local diabetes specialists have agreed which groups of patients would gain most health benefit from using Flash Glucose Monitoring Systems, whilst keeping it affordable for the NHS.

Flash Glucose Monitoring Systems  are routinely commissioned for adult and child patients with type 1 diabetes mellitus in certain circumstances. These criteria can be found in the Commissioning Statement Tracker on the Commissioning Statements page. Requests for other patients, who exhibit exceptionality, will need to go through the IFR process. GPs should NOT initiate any prescriptions for Flash Glucose Monitoring Systems.

Valproate Pregnancy Prevention Programme

The following sections include new information about valproate and pregnancy: Medicines alerts and safety issues; mental health; patient information.

Antibiotic Campaign 2018/19

The antibiotic campaign resources for this year are now live. There are pages for the public/parents/carers and clinicians. See the menus on the left.

Antimicrobial resistance poses a grave threat to health.

Paraffin-containing skin preparations (emollients)

West Yorkshire Fire & Rescue Service has produced YouTube Videos for the public and patients and one for Healthcare Professionals warning that even low-level paraffin based products can increase the risk of a fire developing. The YouTube videos have been added to the following sections of the website for information and discussion:  Medicines Alerts and Safety Issues, Patient Information and Care Homes. There is also information on the Fire Service’s website.


The ratified minutes from the August meeting have been added to the business section of the website for information.

Items which should not routinely be prescribed in Primary Care: Guidance for CCGs

Following the publication of the above NHSE guidance to CCGs; the SWYAPC CCGs intend to commission in line with the guidance and align the Commissioning Statements.

The SWYAPC has also produced a letter to inform Community Pharmacies in Bradford, Calderdale, Kirklees and Wakefield of the local plans regarding the NHSE guidance.